Molecular Testing for Patients With Metastatic Relapse on or Within 1 Year of Adjuvant Endocrine Therapy

Opinion
Video

A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine therapy is crucial for detecting ESR1 mutations and other resistance mechanisms that can inform subsequent treatment selection.

Recent Videos
Hope S. Rugo, MD, FASCO, is featured in this series.
1 expert in this video
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.